Novo Nordisk A/S (NYSE:NVO) Shares Purchased by Advisors Capital Management LLC

Advisors Capital Management LLC grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 7.9% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 8,912 shares of the company’s stock after purchasing an additional 649 shares during the period. Advisors Capital Management LLC’s holdings in Novo Nordisk A/S were worth $767,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Center for Financial Planning Inc. boosted its position in Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after purchasing an additional 123 shares during the period. Albion Financial Group UT grew its stake in shares of Novo Nordisk A/S by 121.4% during the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after acquiring an additional 278 shares in the last quarter. Hager Investment Management Services LLC purchased a new stake in shares of Novo Nordisk A/S during the fourth quarter worth about $46,000. Sound Income Strategies LLC grew its stake in Novo Nordisk A/S by 82.1% during the 4th quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock valued at $46,000 after purchasing an additional 243 shares in the last quarter. Finally, Halbert Hargrove Global Advisors LLC acquired a new position in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $47,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Ratings Changes

NVO has been the subject of several research reports. Stifel Nicolaus lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Morgan Stanley began coverage on Novo Nordisk A/S in a research note on Wednesday, February 12th. They set an “equal weight” rating for the company. Finally, Kepler Capital Markets raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, March 13th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $66.00 on Tuesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The firm’s 50-day moving average is $77.48 and its 200-day moving average is $92.95. Novo Nordisk A/S has a 52-week low of $59.32 and a 52-week high of $148.15. The company has a market cap of $296.18 billion, a price-to-earnings ratio of 20.06, a PEG ratio of 0.90 and a beta of 0.61.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Equities research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a semi-annual dividend, which was paid on Tuesday, April 8th. Investors of record on Monday, March 31st were issued a $0.7874 dividend. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date was Monday, March 31st. This represents a yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 49.54%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.